Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors

被引：27

作者：

Saito, Tatsuhiko ^{[1
]}

Ohnuma, Kei ^{[2
]}

Suzuki, Hiroshi ^{[3
]}

Dang, Nam H. ^{[4
]}

Hatano, Ryou ^{[2
]}

Ninomiya, Hiroki ^{[5
]}

Morimoto, Chikao ^{[2
]}

机构：

[1] Kobari Gen Hosp, Dept Diabet & Metab Internal Med, Noda, Chiba 2788501, Japan

[2] Juntendo Univ, Grad Sch Med, Dept Therapy Dev & Innovat Immune Disorders & Can, Bunkyo Ku, Tokyo 1138421, Japan

[3] Kitakashiwa Suzuki Clin, Kashiwa, Chiba 2770812, Japan

[4] Univ Florida, Div Hematol Oncol, Gainesville, FL 32610 USA

[5] Kobari Gen Hosp, Noda, Chiba 2788501, Japan

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2013年 / 102卷 / 01期

关键词：

DPP-4; CD26; inhibitors; Polyarthropathy; SDF-1; alpha; DIPEPTIDYL-PEPTIDASE-IV; RHEUMATOID-ARTHRITIS; CD26; SITAGLIPTIN; CHEMOKINES; DISEASES;

D O I：

10.1016/j.diabres.2013.07.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1 alpha level. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：E8 / E12

页数：5

共 20 条

[1] THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS OF THE HAND [J].

ALTMAN, R ;

ALARCON, G ;

APPELROUTH, D ;

BLOCH, D ;

BORENSTEIN, D ;

BRANDT, K ;

BROWN, C ;

COOKE, TD ;

DANIEL, W ;

GRAY, R ;

GREENWALD, R ;

HOCHBERG, M ;

HOWELL, D ;

IKE, R ;

KAPILA, P ;

KAPLAN, D ;

KOOPMAN, W ;

LONGLEY, S ;

MCSHANE, DJ ;

MEDSGER, T ;

MICHEL, B ;

MURPHY, W ;

OSIAL, T ;

RAMSEYGOLDMAN, R ;

ROTHSCHILD, B ;

STARK, K ;

WOLFE, F .

ARTHRITIS AND RHEUMATISM, 1990, 33 (11) :1601-1610

[2]

[Anonymous], ARTHRITIS RHEUM

[3] Circulating CD26 is negatively associated with inflammation in human and experimental arthritis [J].

Busso, N ;

Wagtmann, N ;

Herling, C ;

Chobaz-Péclat, V ;

Bischof-Delaloye, A ;

So, A ;

Grouzmann, E .

AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (02) :433-442

[4]

Crickx E, 2013, RHEUMATOL INT

[5]

Cuchacovich M, 2001, CLIN EXP RHEUMATOL, V19, P673

[6] CD26, let it cut or cut it down [J].

De Meester, I ;

Korom, S ;

Van Damme, J ;

Scharpé, S .

IMMUNOLOGY TODAY, 1999, 20 (08) :367-375

[7] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[8] Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis [J].

Eriksson, C. ;

Rantapaa-Dahlqvist, S. ;

Sundqvist, K. G. .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (04) :260-265

[9] Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors [J].

Holst, JJ ;

Deacon, CF .

DIABETOLOGIA, 2005, 48 (04) :612-615

[10] A NEW DIPEPTIDE NAPHTHYLAMIDASE HYDROLYZING GLYCYL-PROLYL-BETA-NAPHTHYLAMIDE [J].

HOPSUHAV.VK ;

GLENNER, GG .

HISTOCHEMIE, 1966, 7 (03) :197-&

← 1 2 →